Top 10 AI-Powered Biotech Stocks to Buy Now

3. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 83

Pfizer Inc. (NYSE:PFE), a global pharmaceutical leader, continues to expand its mRNA vaccine and specialty medicine portfolio while maintaining focus on oncology, immunology, and infectious diseases. The company, widely recognized for its COVID-19 vaccine collaboration with BioNTech, recently announced significant progress with its LP.8.1-adapted COMIRNATY 2025-2026 formula.

In early September 2025, Pfizer Inc. (NYSE:PFE) reported positive Phase 3 topline data showing a fourfold increase in neutralizing antibodies in adults 65+ and high-risk adults 18–64. This adaptive vaccine targets emerging SARS-CoV-2 sublineages, supporting FDA approval and reinforcing PFE’s strategic direction to maintain vaccine efficacy in a changing pandemic landscape. The success highlights the broader potential of Pfizer’s mRNA platform, including applications in cancer immunotherapy.

Beyond vaccines, Pfizer Inc. (NYSE:PFE) is advancing oncology and specialty medicines. Combination therapy PADCEV plus KEYTRUDA has shown improved survival in bladder cancer, while HYMPAVZI continues to progress in hemophilia treatment. These developments illustrate the company’s commitment to high-need therapeutic areas.

Despite regulatory challenges, patent litigation over Paxlovid, and shifts in vaccine demand, the business continues to invest in R&D and strategic partnerships. The company’s focus on adaptive mRNA technology, AI-driven development, and precision medicine underscores its leadership among biotech innovators.